Annexon (ANNX) director receives 175,000 options at $5.39 strike, vesting over 3 years
Rhea-AI Filing Summary
Annexon, Inc. reported that director Mark S. Blumenkranz received a grant of 175,000 stock options on August 10, 2026. The options have an exercise price of $5.39 per share and expire on August 10, 2036. According to the vesting terms, 1/36 of the shares vest monthly starting from August 10, 2026, so all 175,000 underlying common shares are scheduled to be fully vested and exercisable on the third anniversary of that date, subject to his continuous service as a director.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Blumenkranz Mark S.
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) F1 | 175,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 175,000 shares (Direct)
Footnotes (1)
- F1. 1/36th of the shares subject to the option vest on each monthly anniversary measured from August 10, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date, subject to Reporting Person's continuous service as a director on each such vesting date.
Key Figures
Stock options granted: 175,000 options
Exercise price: $5.39 per share
Options expiration date: August 10, 2036
+2 more
5 metrics
Stock options granted
175,000 options
Grant of Stock Option (Right to Buy) on August 10, 2026
Exercise price
$5.39 per share
Conversion or exercise price of the granted stock options
Options expiration date
August 10, 2036
Expiration date of the Stock Option (Right to Buy)
Underlying common shares
175,000 shares
Each option corresponds to one share of Annexon common stock
Vesting period
36 months
1/36 of the shares vest monthly from August 10, 2026 over three years
Key Terms
Stock Option (Right to Buy), Vesting Commencement Date, continuous service
3 terms
Stock Option (Right to Buy) financial
"security_title is reported as Stock Option (Right to Buy)"
Vesting Commencement Date financial
"measured from August 10, 2026 (the "Vesting Commencement Date")"
The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.
continuous service financial
"subject to Reporting Person's continuous service as a director"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did Annexon (ANNX) director Mark S. Blumenkranz report in this Form 4?
Director Mark S. Blumenkranz reported receiving a grant of 175,000 stock options for Annexon, Inc. These options were awarded on August 10, 2026 and represent the right to buy Annexon common stock under specified terms and conditions.
How many stock options were granted to the Annexon (ANNX) director and at what exercise price?
The director was granted 175,000 stock options with an exercise price of $5.39 per share. Each option is a right to buy one share of Annexon common stock at that price once the option has vested and before expiration.
What is the vesting schedule for the 175,000 Annexon (ANNX) stock options?
The options vest in 36 equal monthly installments, with 1/36 of the shares vesting each month from August 10, 2026. All shares are expected to be fully vested and exercisable by the third anniversary, subject to continuous service as a director.
When do the newly granted Annexon (ANNX) stock options expire?
The granted stock options expire on August 10, 2036. After that expiration date, any unexercised portion of the 175,000 options can no longer be used to purchase Annexon common stock at the $5.39 exercise price.
What will Mark S. Blumenkranz’s holdings be after this Annexon (ANNX) option grant?
Following this grant, the Form 4 shows 175,000 derivative securities (stock options) held directly. These options are separate from any common stock holdings and represent rights to acquire Annexon common shares in the future, subject to vesting and exercise.
Is the Annexon (ANNX) director’s option grant under a Rule 10b5-1 trading plan?
The filing’s Rule 10b5-1 checkbox is not marked as affirmative. The transaction is reported as a grant/award acquisition of options rather than an open-market trade executed under a pre-arranged Rule 10b5-1 trading plan.